Oak Thistle LLC Has $426,000 Stake in The Cooper Companies, Inc. (NASDAQ:COO)

Oak Thistle LLC reduced its position in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 47.4% in the 4th quarter, HoldingsChannel.com reports. The firm owned 4,635 shares of the medical device company’s stock after selling 4,179 shares during the quarter. Oak Thistle LLC’s holdings in Cooper Companies were worth $426,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in COO. Ashton Thomas Securities LLC acquired a new stake in shares of Cooper Companies during the third quarter worth $25,000. Covestor Ltd increased its position in Cooper Companies by 144.9% during the third quarter. Covestor Ltd now owns 338 shares of the medical device company’s stock worth $37,000 after acquiring an additional 200 shares during the period. Brown Brothers Harriman & Co. raised its stake in Cooper Companies by 191.0% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company’s stock worth $46,000 after purchasing an additional 275 shares in the last quarter. Friedenthal Financial bought a new stake in Cooper Companies in the 3rd quarter valued at about $50,000. Finally, Cromwell Holdings LLC bought a new stake in Cooper Companies in the 3rd quarter valued at about $52,000. 24.39% of the stock is currently owned by institutional investors.

Cooper Companies Stock Up 1.5 %

COO opened at $92.04 on Friday. The Cooper Companies, Inc. has a twelve month low of $84.76 and a twelve month high of $112.38. The company’s 50-day moving average price is $96.98 and its two-hundred day moving average price is $98.89. The stock has a market cap of $18.37 billion, a price-to-earnings ratio of 47.20, a PEG ratio of 2.29 and a beta of 0.99. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings data on Thursday, December 5th. The medical device company reported $1.04 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.04. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.03 billion. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The firm’s revenue for the quarter was up 9.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.87 EPS. As a group, equities analysts expect that The Cooper Companies, Inc. will post 3.98 earnings per share for the current year.

Analysts Set New Price Targets

COO has been the topic of a number of recent research reports. Morgan Stanley lowered their price objective on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research note on Friday, December 6th. StockNews.com cut Cooper Companies from a “buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Citigroup cut their price objective on shares of Cooper Companies from $116.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, December 6th. Wells Fargo & Company increased their price objective on shares of Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a research note on Friday, December 6th. Finally, Needham & Company LLC restated a “hold” rating on shares of Cooper Companies in a research report on Friday, December 6th. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, Cooper Companies currently has a consensus rating of “Moderate Buy” and a consensus price target of $117.00.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.